| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8980839 | SUN PHARM | Topical aqueous nanomicellar, ophthalmic solutions and uses thereof |
Aug, 2033
(9 years from now) | |
| US9937225 | SUN PHARM | Topical formulations and uses thereof |
Aug, 2033
(9 years from now) | |
| US10441630 | SUN PHARM | Topical formulations and uses thereof |
Aug, 2033
(9 years from now) | |
| US10918694 | SUN PHARM | Topical cyclosporine-containing formulations and uses thereof |
Feb, 2037
(13 years from now) | |
Cequa is owned by Sun Pharm.
Cequa contains Cyclosporine.
Cequa has a total of 4 drug patents out of which 0 drug patents have expired.
Cequa was authorised for market use on 14 August, 2018.
Cequa is available in solution;ophthalmic dosage forms.
Cequa can be used as increase tear production in patients with keratoconjunctivitis sicca (dry eye)..
The generics of Cequa are possible to be released after 28 February, 2037.
Drugs and Companies using CYCLOSPORINE ingredient
Market Authorisation Date: 14 August, 2018
Treatment: Increase tear production in patients with keratoconjunctivitis sicca (dry eye).
Dosage: SOLUTION;OPHTHALMIC
CEQUA family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic